Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Phase measurement of interference fringes is an integral part of several fields in optics. Using simple straight sinusoidal fringe patterns, we describe the relationship between fringe position or phase to the centroid position when these fringes are incident on a position sensitive detector. With detailed descriptions and some experimental results, we show that a phenomenal sensitivity is possible in principle with what we believe is a new approach of phase measurement, and excellent sensitivity is readily achieved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1364/ao.46.005137 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Timing Matters: How Daily Rhythms Affect Remote Ischemic Postconditioning Therapy for Stroke.
Stroke
September 2025
Departments of Radiology and Neurology, Neuroprotection Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston (E.L., R.M.P., K.H., E.H.L., E.E.).
Background: Despite promising preclinical results, remote limb ischemic postconditioning efficacy in human stroke treatment remains unclear, with mixed clinical trial outcomes. A potential reason for translational difficulties could be differences in circadian rhythms between nocturnal rodent models and diurnal humans.
Methods: Male C57BL/6J mice were subjected to transient focal cerebral ischemia and then exposed to remote postconditioning during their active or inactive phase and euthanized at 24 hours and 3 days.
Smartphone-assisted image analysis for orthophosphate in aqueous samples with CTAB-enhanced extraction.
Anal Methods
September 2025
Department of Chemistry, Faculty of Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran.
This study introduces a new, highly sensitive, and reliable method for detecting and measuring orthophosphate in environmental water samples. This method combines cetyltrimethylammonium bromide (CTAB)-mediated coacervation extraction with digital image-based colorimetry, providing a robust and efficient approach for orthophosphate analysis. In this system, CTAB, a cationic surfactant, serves a dual role as both an ion-pairing agent and an extraction medium.
View Article and Find Full Text PDFPreclinical Ischemic Stroke Multicenter (PRISM) Trials Collective Statement: Opportunities, Challenges, and Recommendations for a New Era.
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFImproving Patient Engagement in Phase 2 Clinical Trials With a Trial-Specific Patient Decision Aid: Development and Usability Study.
J Med Internet Res
September 2025
Department of Precision Medicine, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands, 31 433883549.
Background: Making informed decisions about clinical trial participation can be overwhelming for patients due to the complexity of trial information, potential risks and benefits, and the emotional burden of a recent diagnosis. Patient decision aids (PDAs) simplify this process by providing clear information on treatment options, empowering patients to actively participate in shared decision-making with their doctors. While PDAs have shown promise in various health care contexts, their use in clinical trials, particularly in the form of trial-specific patient decision aids (tPDAs), remains underused.
View Article and Find Full Text PDFEarly itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial.
J Dermatolog Treat
December 2025
Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Background: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
Objectives: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.
Methods: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed.